#Verismo_Therapeutics
LightNews LightNews
newsen.bsky.social
Verismo Therapeutics Enhances Pipeline with Innovative KIR-CAR Therapy for Solid Tumors#United_States#Philadelphia#Verismo_Therapeutics#CLDN6#KIR-CAR
Verismo Therapeutics Enhances Pipeline with Innovative KIR-CAR Therapy for Solid Tumors
Verismo Therapeutics has broadened its KIR-CAR approach by introducing a new therapy targeting Claudin 6, enhancing treatment options for solid tumors alongside mesothelin targeting.
third-news.com
July 21, 2026 at 12:26 PM
newsen.bsky.social
Verismo Therapeutics Reveals Promising Preclinical Findings for SynKIR™-310 KIR-CAR in B Cell Malignancies#USA#San_Diego#Verismo_Therapeutics#SynKIR™-310#KIR-CAR
Verismo Therapeutics Reveals Promising Preclinical Findings for SynKIR™-310 KIR-CAR in B Cell Malignancies
Verismo Therapeutics showcases new preclinical data for SynKIR™-310 KIR-CAR that indicates enhanced anti-tumor activity and potential in treating B cell malignancies.
third-news.com
April 21, 2026 at 4:22 PM
newsen.bsky.social
Innovative Findings from Verismo Therapeutics' STAR-101 Phase 1 Trial of SynKIR™-110 Revealed at AACR 2026#United_States#Philadelphia#Verismo_Therapeutics#KIR-CAR#SynKIR™-110
Innovative Findings from Verismo Therapeutics' STAR-101 Phase 1 Trial of SynKIR™-110 Revealed at AACR 2026
Preliminary data from Verismo Therapeutics’ STAR-101 trial of SynKIR™-110 KIR-CAR shows promise in solid tumor treatments, showcasing safety and efficacy.
third-news.com
April 20, 2026 at 5:24 PM
newsen.bsky.social
Verismo Therapeutics Unveils Groundbreaking KIR-CAR Data at AACR Annual Meeting 2026#USA#San_Diego#Immuno-Oncology#Verismo_Therapeutics#SynKIR
Verismo Therapeutics Unveils Groundbreaking KIR-CAR Data at AACR Annual Meeting 2026
At the AACR Annual Meeting 2026, Verismo Therapeutics will present promising Phase 1 data on its innovative KIR-CAR therapies, SynKIR™-110 and SynKIR™-310, highlighting advancements in immunotherapy for various cancers.
third-news.com
March 17, 2026 at 11:07 PM
newsen.bsky.social
Verismo Therapeutics Reveals Groundbreaking Data on SynKIR™-310 CAR T Therapy at ASH 2025#USA#Philadelphia#CAR_T_Therapy#Verismo_Therapeutics#SynKIR-310
Verismo Therapeutics Reveals Groundbreaking Data on SynKIR™-310 CAR T Therapy at ASH 2025
Verismo Therapeutics presented new preclinical findings on SynKIR™-310, showcasing enhanced tumor control and reduced cytokine release compared to traditional CAR-T therapies.
third-news.com
December 9, 2025 at 1:51 PM
newsen.bsky.social
Verismo Therapeutics Unveils New Preclinical Findings for SynKIR™-110 at SITC 2025#USA#Philadelphia#CAR_T_Therapy#Verismo_Therapeutics#SynKIR™
Verismo Therapeutics Unveils New Preclinical Findings for SynKIR™-110 at SITC 2025
Verismo Therapeutics has shared groundbreaking preclinical data on SynKIR™-110 during SITC 2025, showcasing its superior efficacy and safety in targeting solid tumors.
third-news.com
November 10, 2025 at 4:07 PM
newsen.bsky.social
Verismo Therapeutics Prepares for Key Presentations at Upcoming Conferences#USA#Philadelphia#Clinical_Trials#Verismo_Therapeutics#KIR-CAR
Verismo Therapeutics Prepares for Key Presentations at Upcoming Conferences
Verismo Therapeutics is set to present at the SITC and ASH meetings, showcasing its innovative KIR-CAR technology and preclinical data.
third-news.com
November 5, 2025 at 1:48 PM
newsen.bsky.social
Verismo Therapeutics Set to Showcase Innovative KIR-CAR Technology at iMig 2025#USA#Philadelphia#Verismo_Therapeutics#Mesothelioma#KIR-CAR
Verismo Therapeutics Set to Showcase Innovative KIR-CAR Technology at iMig 2025
Verismo Therapeutics announces participation in iMig 2025 to present STAR-101, a clinical trial on innovative CAR T technology targeting mesothelioma.
third-news.com
October 23, 2025 at 12:33 PM
newsen.bsky.social
Verismo Therapeutics Advances Follicular Lymphoma Treatment in CELESTIAL-301 Trial#USA#Philadelphia#IFLI#Verismo_Therapeutics#CELESTIAL-301
Verismo Therapeutics Advances Follicular Lymphoma Treatment in CELESTIAL-301 Trial
Verismo Therapeutics has treated its first follicular lymphoma patient in the CELESTIAL-301 trial, enhancing collaboration with IFLI to explore new therapeutic options.
third-news.com
October 2, 2025 at 12:30 PM
newsen.bsky.social
Verismo and Miltenyi Biotec's Collaboration to Enhance CAR T Cell Therapies#USA#Philadelphia#Verismo_Therapeutics#Miltenyi_Biotec#KIR-CAR
Verismo and Miltenyi Biotec's Collaboration to Enhance CAR T Cell Therapies
The partnership between Verismo Therapeutics and Miltenyi Biotec aims to advance clinical programs for CAR T therapies, vital for treating solid tumors.
third-news.com
September 25, 2025 at 12:41 PM
newsen.bsky.social
Verismo Therapeutics Celebrates Third Year as a Best Place to Work in Philadelphia#USA#Philadelphia#Employee_Satisfaction#Verismo_Therapeutics#KIR-CAR
Verismo Therapeutics Celebrates Third Year as a Best Place to Work in Philadelphia
For the third consecutive year, Verismo Therapeutics has been recognized as one of the Best Places to Work by the Philadelphia Business Journal, reflecting its commitment to employee satisfaction.
third-news.com
July 29, 2025 at 12:37 PM
newsen.bsky.social
Upcoming Presentation of Innovative CAR T Therapy at ASCO 2025 by Verismo Therapeutics#USA#Chicago#Verismo_Therapeutics#ASCO_2025#KIR-CAR
Upcoming Presentation of Innovative CAR T Therapy at ASCO 2025 by Verismo Therapeutics
Verismo Therapeutics will unveil promising updates on the innovative KIR-CAR platform during their poster presentation at ASCO 2025.
third-news.com
May 23, 2025 at 12:12 PM
newsen.bsky.social
Verismo Therapeutics to Present Groundbreaking KIR-CAR Research at ASCO 2025 Conference#USA#Chicago#Verismo_Therapeutics#ASCO_2025#KIR-CAR
Verismo Therapeutics to Present Groundbreaking KIR-CAR Research at ASCO 2025 Conference
Verismo Therapeutics will present its latest KIR-CAR technology advancements during ASCO 2025, promising new hope for cancer patients.
third-news.com
April 24, 2025 at 12:31 PM
newsen.bsky.social
Verismo Therapeutics Initiates Phase 1 Trial of SynKIR™-310 for Advanced Lymphomas#United_States#Denver#Verismo_Therapeutics#SynKIR-310#CELESTIAL-301
Verismo Therapeutics Initiates Phase 1 Trial of SynKIR™-310 for Advanced Lymphomas
Verismo Therapeutics has announced the start of its Phase 1 CELESTIAL-301 trial for SynKIR™-310, targeting relapsed B cell Non-Hodgkin Lymphomas. The trial aims to offer new treatment options for patients facing these challenging cancers.
third-news.com
January 10, 2025 at 1:32 PM
newsen.bsky.social
Verismo Therapeutics Partners with IFLI to Boost SynKIR™-310 for Follicular Lymphoma Treatment#USA#Philadelphia#IFLI#Verismo_Therapeutics#SynKIR™-310
Verismo Therapeutics Partners with IFLI to Boost SynKIR™-310 for Follicular Lymphoma Treatment
Verismo Therapeutics announces a strategic investment partnership with IFLI to enhance development of SynKIR™-310 aimed at treating follicular lymphoma.
third-news.com
January 7, 2025 at 1:37 PM
newsen.bsky.social
Merger Boosts Verismo Therapeutics' Clinical Development Opportunities with HLB Group#South_Korea#KIR-CAR_technology#Verismo_Therapeutics#HLB_Innovation#Philadephia
Merger Boosts Verismo Therapeutics' Clinical Development Opportunities with HLB Group
Verismo Therapeutics has finalized a merger with HLB Innovation, enhancing its clinical development and innovation capabilities in cancer therapies.
third-news.com
December 20, 2024 at 1:13 PM